Communiqués Philogen S.p.A.

Actions

PHIL

IT0005373789

Marché Fermé - Borsa Italiana Autres places de cotation 17:44:59 11/06/2024			Varia. 5j.	Varia. 1 janv.
20,8 ^EUR	0,00 %		+1,46 %	+12,43 %

06/06	Les futures en légère hausse le jour de la BCE	AN
05/06	Le Mib en hausse avant la BCE ; STM et Nexi montent en flèche	AN

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Philogen S p A : to attend the Chemical Biology conference at Novo Nordisk on June 8-9, 2024.	24/05	PU
Philogen S p A : to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024.	24/04	PU
Philogen S p A : is delighted to invite you to attend a virtual briefing on April 3, 2024 to discuss the Company’s Full Year 2023 Results.	05/04	PU
Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma	20/02	GL
Philogen S p A : to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024	20/12	PU
Philogen S p A : to attend the Immunotherapy of Cancer Conference (ITOC) in Munich on March 21-23, 2024.	20/12	PU
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities	05/12	GL
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities	05/12	AQ
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors	04/12	GL
Philogen S p A : Ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	06/11	PU
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma	16/10/23	GL
Philogen S p A : Settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	04/10/23	PU
Philogen S p A : Agosto 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	05/09/23	PU
Philogen S p A : kindly invites you to attend a virtual briefing for analysts on 2 October 2023 to discuss Company’s Half Year 2023 Results	05/09/23	PU
Philogen S p A : Luglio 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	01/08/23	PU
Philogen S p A : announces new publication in Nature Chemistry	05/07/23	PU
Philogen S p A : Giugno 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	03/07/23	PU
Philogen S p A : Maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie (Allegato 3F)	09/06/23	PU
Philogen S p A : kindly invites you to attend a virtual briefing for analysts on 5 June 2023 to discuss the Company’s latest updates.	05/06/23	PU
Philogen Announces Clinical Trial Collaboration with MSD	01/06/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Philogen S.p.A.

Actions

PHIL

IT0005373789

Communiqués

Filtres